Last reviewed · How we verify
Risperidone, divalproex
This combination uses risperidone (a dopamine antagonist) and divalproex (a histone deacetylase inhibitor and mood stabilizer) together to treat bipolar disorder and related psychiatric conditions.
This combination uses risperidone (a dopamine antagonist) and divalproex (a histone deacetylase inhibitor and mood stabilizer) together to treat bipolar disorder and related psychiatric conditions. Used for Bipolar disorder (acute mania and maintenance treatment), Schizophrenia with mood instability.
At a glance
| Generic name | Risperidone, divalproex |
|---|---|
| Sponsor | Nathan Kline Institute for Psychiatric Research |
| Drug class | Atypical antipsychotic + anticonvulsant mood stabilizer combination |
| Target | Dopamine D2 receptor (risperidone); histone deacetylase / GABA pathway (divalproex) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | FDA-approved |
Mechanism of action
Risperidone blocks dopamine D2 receptors to reduce psychotic symptoms and agitation, while divalproex stabilizes mood through multiple mechanisms including GABA enhancement and histone deacetylase inhibition. The combination targets both acute psychotic symptoms and mood stabilization in bipolar disorder.
Approved indications
- Bipolar disorder (acute mania and maintenance treatment)
- Schizophrenia with mood instability
Common side effects
- Weight gain
- Sedation
- Tremor
- Extrapyramidal symptoms
- Gastrointestinal disturbance
- Metabolic effects (hyperglycemia, dyslipidemia)
Key clinical trials
- Τhe Combination of Pharmacotherapy With RECOVERYTRSGR and RECOVERYTRSBDGR. (PHASE4)
- Measurement of Treatment Effects (EARLY_PHASE1)
- Definitive Selection of Neuroimaging Biomarkers for the Diagnosis and Treatment to Common Mental Disorders (NA)
- Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies
- Efficacy of Hydroxyzine for Patients With Panic Disorder (PHASE4)
- Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications (PHASE4)
- Cost- Effectiveness and Quality of Life Assessment in Mood Disorder (PHASE4)
- Placebo Controlled Trial of Valproate and Risperidone in Young Children With Bipolar Disorders (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Risperidone, divalproex CI brief — competitive landscape report
- Risperidone, divalproex updates RSS · CI watch RSS
- Nathan Kline Institute for Psychiatric Research portfolio CI